{
    "Trade/Device Name(s)": [
        "Dimension\u00ae Hemoglobin A1C Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K173909",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160571"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "June 11, 2018",
    "Summary Letter Received Date": "June 12, 2018",
    "Submission Date": "July 12, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Anticoagulated venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Na Fluoride/Na2-EDTA tube",
        "Lithium Heparin tube",
        "Na Fluoride/K-Oxalate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Dimension\u00ae RxL clinical chemistry system"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric inhibition immunoassay",
        "Absorbance spectroscopy"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens Dimension Hemoglobin A1c assay for quantitative determination of HbA1c in whole blood using turbidimetric inhibition immunoassay on Dimension clinical chemistry system.",
    "Indications for Use Summary": "In vitro diagnostic assay for the quantitative determination of HbA1c in anticoagulated venous whole blood as an aid in diagnosis and monitoring of long-term blood glucose control in patients with diabetes mellitus and identification of patients at risk for developing diabetes mellitus.",
    "fda_folder": "Clinical Chemistry"
}